[1] M. Campbell et al., "Protein arginine methyltransferase 1-directed methylation of Kaposi sarcoma-associated herpesvirus latency-associated nuclear antigen," (in eng), The Journal of biological chemistry, vol. 287, no. 8, pp. 5806-5818, 2012.
[2] F. Herrmann, P. Pably, C. Eckerich, M. T. Bedford, and F. O. Fackelmayer, "Human protein arginine methyltransferases in vivo--distinct properties of eight canonical members of the PRMT family," (in eng), J. Cell Sci., vol. 122, no. Pt 5, pp. 667-77, Mar 1 2009.
[3] T. R. Ferreira et al., "PRMT7 regulates RNA-binding capacity and protein stability in Leishmania parasites," (in eng), Nucleic Acids Res., vol. 48, no. 10, pp. 5511-5526, Jun 4 2020.
[4] Y.-C. Wang, S. E. Peterson, and J. F. Loring, "Protein post-translational modifications and regulation of pluripotency in human stem cells," Cell Res., vol. 24, no. 2, pp. 143-160, 2014.
[5] J. M. Hsu, C. W. Li, Y. J. Lai, and M. C. Hung, "Posttranslational Modifications of PD-L1 and Their Applications in Cancer Therapy," (in eng), Cancer Res., vol. 78, no. 22, pp. 6349-6353, Nov 15 2018.
[6] V. Singh, M. Ram, R. Kumar, R. Prasad, B. K. Roy, and K. K. Singh, "Phosphorylation: Implications in Cancer," (in eng), Protein J., vol. 36, no. 1, pp. 1-6, Feb 2017.
[7] M. Audagnotto and M. Dal Peraro, "Protein post-translational modifications: In silico prediction tools and molecular modeling," Computational and structural biotechnology journal, vol. 15, pp. 307-319, 2017.
[8] R. S. Blanc and S. Richard, "Arginine Methylation: The Coming of Age," (in eng), Mol. Cell, vol. 65, no. 1, pp. 8-24, Jan 5 2017.
[9] J. Zhang, L. Jing, M. Li, L. He, and Z. Guo, "Regulation of histone arginine methylation/demethylation by methylase and demethylase," Mol. Med. Report., vol. 19, no. 5, pp. 3963-3971, 2019.
[10] J. Liu et al., "Arginine methylation‐dependent LSD1 stability promotes invasion and metastasis of breast cancer," EMBO reports, vol. 21, no. 2, p. e48597, 2020.
[11] Y. Takahashi, H. Daitoku, A. Yokoyama, K. Nakayama, J. D. Kim, and A. Fukamizu, "The C. elegans PRMT-3 possesses a type III protein arginine methyltransferase activity," (in eng), J. Recept. Signal Transduct. Res., vol. 31, no. 2, pp. 168-72, Apr 2011.
[12] M. M. Szewczyk et al., "Pharmacological inhibition of PRMT7 links arginine monomethylation to the cellular stress response," (in eng), Nat Commun, vol. 11, no. 1, p. 2396, May 14 2020.
[13] L. Fang et al., "SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis," (in eng), Cancer Cell, vol. 34, no. 1, pp. 103-118.e9, Jul 9 2018.
[14] R. M. Baldwin, A. Morettin, and J. Côté, "Role of PRMTs in cancer: Could minor isoforms be leaving a mark?," World J. Biol. Chem., vol. 5, no. 2, p. 115, 2014.
[15] K. Jain and S. G. Clarke, "PRMT7 as a unique member of the protein arginine methyltransferase family: A review," (in eng), Arch. Biochem. Biophys., vol. 665, pp. 36-45, Apr 15 2019.
[16] J. Brumbaugh et al., "Nudt21 Controls Cell Fate by Connecting Alternative Polyadenylation to Chromatin Signaling," (in eng), Cell, vol. 172, no. 1-2, pp. 106-120.e21, Jan 11 2018.
[17] J. Guhaniyogi and G. Brewer, "Regulation of mRNA stability in mammalian cells," (in eng), Gene, vol. 265, no. 1-2, pp. 11-23, Mar 7 2001.
[18] D. Liu et al., "Systematic variation in mRNA 3'-processing signals during mouse spermatogenesis," (in eng), Nucleic Acids Res., vol. 35, no. 1, pp. 234-46, 2007.
[19] S. Bienroth, W. Keller, and E. Wahle, "Assembly of a processive messenger RNA polyadenylation complex," (in eng), EMBO J., vol. 12, no. 2, pp. 585-94, Feb 1993.
[20] B. Tian and J. L. Manley, "Alternative polyadenylation of mRNA precursors," (in eng), Nat. Rev. Mol. Cell Biol., vol. 18, no. 1, pp. 18-30, Jan 2017.
[21] D. C. Di Giammartino, K. Nishida, and J. L. Manley, "Mechanisms and consequences of alternative polyadenylation," (in eng), Mol. Cell, vol. 43, no. 6, pp. 853-66, Sep 16 2011.
[22] M. Hoque et al., "Analysis of alternative cleavage and polyadenylation by 3' region extraction and deep sequencing," (in eng), Nat. Methods, vol. 10, no. 2, pp. 133-9, Feb 2013.
[23] R. Sandberg, J. R. Neilson, A. Sarma, P. A. Sharp, and C. B. Burge, "Proliferating cells express mRNAs with shortened 3' untranslated regions and fewer microRNA target sites," (in eng), Science, vol. 320, no. 5883, pp. 1643-7, Jun 20 2008.
[24] S. Tan et al., "NUDT21 negatively regulates PSMB2 and CXXC5 by alternative polyadenylation and contributes to hepatocellular carcinoma suppression," (in eng), Oncogene, vol. 37, no. 35, pp. 4887-4900, Aug 2018.
[25] M. Xiong et al., "NUDT21 inhibits bladder cancer progression through ANXA2 and LIMK2 by alternative polyadenylation," (in eng), Theranostics, vol. 9, no. 24, pp. 7156-7167, 2019.
[26] "Prostate cancer," (in eng), Nurs. Stand., vol. 30, no. 40, p. 17, Jun 1 2016.
[27] J. Ferlay et al., "Cancer statistics for the year 2020: An overview," Int. J. Cancer, 2021.
[28] J. Ferlay et al., "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012," (in eng), Int. J. Cancer, vol. 136, no. 5, pp. E359-86, Mar 1 2015.
[29] E. A. Klein, J. Ciezki, P. A. Kupelian, and A. Mahadevan, "Outcomes for intermediate risk prostate cancer: are there advantages for surgery, external radiation, or brachytherapy?," (in eng), Urol. Oncol., vol. 27, no. 1, pp. 67-71, Jan-Feb 2009.
[30] M. Kirby, C. Hirst, and E. D. Crawford, "Characterising the castration-resistant prostate cancer population: a systematic review," (in eng), Int. J. Clin. Pract., vol. 65, no. 11, pp. 1180-92, Nov 2011.
[31] D. Robinson et al., "Integrative clinical genomics of advanced prostate cancer," (in eng), Cell, vol. 161, no. 5, pp. 1215-1228, May 21 2015.
[32] H. I. Scher et al., "Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study," (in eng), Lancet, vol. 375, no. 9724, pp. 1437-46, Apr 24 2010.
[33] S. M. Blazie, H. C. Geissel, H. Wilky, R. Joshi, J. Newbern, and M. Mangone, "Alternative Polyadenylation Directs Tissue-Specific miRNA Targeting in Caenorhabditis elegans Somatic Tissues," (in eng), Genetics, vol. 206, no. 2, pp. 757-774, Jun 2017.
[34] A. Guo et al., "Immunoaffinity enrichment and mass spectrometry analysis of protein methylation," Mol. Cell. Proteomics, vol. 13, no. 1, pp. 372-387, 2014.
[35] H. C. Lee et al., "YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer," (in eng), Oncogene, vol. 40, no. 13, pp. 2407-2421, Apr 2021.
[36] Z. A. Wang, R. Toivanen, S. K. Bergren, P. Chambon, and M. M. Shen, "Luminal cells are favored as the cell of origin for prostate cancer," (in eng), Cell Rep., vol. 8, no. 5, pp. 1339-46, Sep 11 2014.
[37] A. Valinezhad Orang, R. Safaralizadeh, and M. Kazemzadeh-Bavili, "Mechanisms of miRNA-Mediated Gene Regulation from Common Downregulation to mRNA-Specific Upregulation," (in eng), Int J Genomics, vol. 2014, p. 970607, 2014.
[38] A. Quattrone and E. Dassi, "The architecture of the human RNA-binding protein regulatory network," IScience, vol. 21, pp. 706-719, 2019.
[39] C. P. Masamha et al., "CFIm25 links alternative polyadenylation to glioblastoma tumour suppression," Nature, vol. 510, no. 7505, pp. 412-416, 2014.
[40] J.-C. Lou et al., "Silencing NUDT21 attenuates the mesenchymal identity of glioblastoma cells via the NF-κB pathway," Front. Mol. Neurosci., vol. 10, p. 420, 2017.
[41] L. Zhang and W. Zhang, "Knockdown of NUDT21 inhibits proliferation and promotes apoptosis of human K562 leukemia cells through ERK pathway," Cancer Manag. Res., vol. 10, p. 4311, 2018.